Sinil Pharmaceutical Co., Ltd. (KOSDAQ:012790)

Sinil Pharmaceutical Income Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	80,972	89,440	89,135	80,007	61,754	61,438
Other Revenue	-0	-0	-	-0	-	-
Revenue	80,972	89,440	89,135	80,007	61,754	61,438
Revenue Growth (YoY)	-11.70%	0.34%	11.41%	29.56%	0.52%	1.30%
Cost of Revenue	44,472	48,774	51,565	44,362	37,313	37,234
Gross Profit	36,500	40,666	37,570	35,645	24,441	24,204
Selling, General & Admin	21,333	21,238	19,491	17,623	15,574	15,522
Research & Development	2,704	2,802	2,979	3,264	194.52	784.55
Other Operating Expenses	421.1	347.33	355.82	378.68	374.75	395.92
Operating Expenses	24,650	25,445	23,579	21,989	16,459	17,583
Operating Income	11,850	15,222	13,991	13,656	7,982	6,621
Interest Expense	-21.76	-26.97	-26.13	-6.05	-9.72	-13.24
Interest & Investment Income	1,163	1,074	849.37	352.84	184.48	224.04
Currency Exchange Gain (Loss)	-15.17	43.68	-59.59	90.91	26.14	4.22
Other Non Operating Income (Expenses)	491.81	217.24	1,379	899.91	14.64	1,226
EBT Excluding Unusual Items	13,468	16,530	16,134	14,994	8,197	8,062
Gain (Loss) on Sale of Investments	-26.81	-26.81	-532.61	-478.44	115.48	-11.37
Gain (Loss) on Sale of Assets	-295.1	3.72	-641.55	221.3	14	13.42
Asset Writedown	31	31	-7	-92.08	14.5	97.5
Pretax Income	13,177	16,538	14,953	14,645	8,341	8,162
Income Tax Expense	1,866	2,237	1,312	2,488	1,663	617.51
Net Income	11,311	14,301	13,641	12,157	6,679	7,544
Net Income to Common	11,311	14,301	13,641	12,157	6,679	7,544
Net Income Growth	-24.92%	4.83%	12.21%	82.02%	-11.47%	3.96%
Shares Outstanding (Basic)	-	12	12	11	11	11
Shares Outstanding (Diluted)	-	12	12	11	11	11
Shares Change (YoY)	-	-0.02%	3.94%	-1.05%	-0.11%	-2.91%
EPS (Basic)	-	1237.13	1179.82	1092.89	594.11	670.34
EPS (Diluted)	-	1237.13	1179.82	1092.89	594.11	670.34
EPS Growth	-	4.86%	7.95%	83.95%	-11.37%	7.08%
Free Cash Flow	7,957	12,327	1,551	3,336	7,820	2,261
Free Cash Flow Per Share	-	1066.39	134.13	299.94	695.63	200.87
Gross Margin	45.08%	45.47%	42.15%	44.55%	39.58%	39.40%
Operating Margin	14.64%	17.02%	15.70%	17.07%	12.93%	10.78%
Profit Margin	13.97%	15.99%	15.30%	15.20%	10.81%	12.28%
Free Cash Flow Margin	9.83%	13.78%	1.74%	4.17%	12.66%	3.68%
EBITDA	19,078	20,828	19,353	18,088	12,518	11,053
EBITDA Margin	23.56%	23.29%	21.71%	22.61%	20.27%	17.99%
D&A For EBITDA	7,228	5,607	5,361	4,432	4,536	4,432
EBIT	11,850	15,222	13,991	13,656	7,982	6,621
EBIT Margin	14.64%	17.02%	15.70%	17.07%	12.93%	10.78%
Effective Tax Rate	14.16%	13.53%	8.77%	16.99%	19.93%	7.57%
Advertising Expenses	-	980.01	1,059	762.13	157.25	206.15

Source: S&P Global Market Intelligence. Standard template. Financial Sources.